Tak Mao Chan

29.3k total citations · 3 hit papers
442 papers, 13.2k citations indexed

About

Tak Mao Chan is a scholar working on Nephrology, Rheumatology and Epidemiology. According to data from OpenAlex, Tak Mao Chan has authored 442 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Nephrology, 131 papers in Rheumatology and 84 papers in Epidemiology. Recurrent topics in Tak Mao Chan's work include Systemic Lupus Erythematosus Research (126 papers), Renal Diseases and Glomerulopathies (83 papers) and Dialysis and Renal Disease Management (71 papers). Tak Mao Chan is often cited by papers focused on Systemic Lupus Erythematosus Research (126 papers), Renal Diseases and Glomerulopathies (83 papers) and Dialysis and Renal Disease Management (71 papers). Tak Mao Chan collaborates with scholars based in Hong Kong, China and United States. Tak Mao Chan's co-authors include Susan Yung, Kar Neng Lai, Desmond Y. H. Yap, Sydney Tang, Colin Tang, Chak Sing Lau, Fu Keung Li, Kwok Wah Chan, Fu–Keung Li and Ignatius K.P. Cheng and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Tak Mao Chan

416 papers receiving 12.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis

2000 671 citations Tak Mao Chan, Kwok Wah Chan et al. profile →
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS

2024 120 citations Brad H. Rovin, Tak Mao Chan et al. profile →
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

2023 100 citations Tak Mao Chan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tak Mao Chan Hong Kong	57	4.8k	4.5k	3.1k	2.2k	2.2k	442	13.2k
Kar Neng Lai Hong Kong	55	5.9k 1.2×	1.7k 0.4×	2.1k 0.7×	1.9k 0.9×	1.2k 0.6×	354	12.9k
William G. Couser United States	75	8.3k 1.7×	2.0k 0.4×	3.6k 1.2×	1.1k 0.5×	1.1k 0.5×	217	15.7k
Lee A. Hebert United States	49	4.8k 1.0×	2.6k 0.6×	2.2k 0.7×	1.2k 0.6×	360 0.2×	147	10.9k
Takashi Wada Japan	55	2.9k 0.6×	1.4k 0.3×	2.8k 0.9×	1.1k 0.5×	429 0.2×	454	13.5k
Pier Luigi Meroni Italy	81	3.1k 0.6×	18.0k 4.0×	9.0k 2.9×	2.3k 1.1×	1.6k 0.8×	621	28.6k
Fokko J. van der Woude Netherlands	59	2.7k 0.5×	1.8k 0.4×	2.4k 0.8×	1.9k 0.9×	491 0.2×	261	13.5k
Piergiorgio Messa Italy	48	2.8k 0.6×	1.5k 0.3×	938 0.3×	2.4k 1.1×	2.6k 1.2×	330	7.9k
Beverley J. Hunt United Kingdom	65	1.5k 0.3×	2.8k 0.6×	2.2k 0.7×	2.0k 0.9×	393 0.2×	340	19.3k
Christophe Legendre France	76	4.3k 0.9×	726 0.2×	3.6k 1.2×	3.6k 1.6×	1.4k 0.6×	426	18.5k
Glen S. Markowitz United States	63	7.0k 1.4×	1.3k 0.3×	1.7k 0.5×	840 0.4×	388 0.2×	195	13.5k

Countries citing papers authored by Tak Mao Chan

Since Specialization

Citations

This map shows the geographic impact of Tak Mao Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tak Mao Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tak Mao Chan more than expected).

Fields of papers citing papers by Tak Mao Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tak Mao Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tak Mao Chan. The network helps show where Tak Mao Chan may publish in the future.

Co-authorship network of co-authors of Tak Mao Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Tak Mao Chan. A scholar is included among the top collaborators of Tak Mao Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tak Mao Chan. Tak Mao Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yap, Desmond YH, et al.. (2025). Lupus Nephritis and Chronic Kidney Disease: A Scoping Review. Nephrology. 30(1). e14427–e14427.

Ma, Jing, Kun Wang, Jiangwen Zhang, et al.. (2024). P-cadherin mechanoactivates tumor-mesothelium metabolic coupling to promote ovarian cancer metastasis. Cell Reports. 44(1). 115096–115096. 4 indexed citations

Yung, Susan & Tak Mao Chan. (2023). Endothelial cell activation and glycocalyx shedding - potential as biomarkers in patients with lupus nephritis. Frontiers in Immunology. 14. 1251876–1251876. 7 indexed citations

Chan, Eugene Yu-hin, et al.. (2021). Demographics and long‐term outcomes of children with end‐stage kidney disease: A 20‐year territory‐wide study. Nephrology. 27(2). 171–180. 15 indexed citations

Pecoits‐Filho, Roberto, Tak Mao Chan, Elise Hardy, Kin-Hung P. Yu, & Steven Fishbane. (2020). Roxadustat Treatment Results in Consistent Improvements in Hemoglobin (Hb) vs. Placebo: An Analysis of Three Multinational Randomized Clinical Trials in Patients with Non-Dialysis-Dependent CKD (NDD-CKD). Journal of the American Society of Nephrology. 31(10S). 2–2. 1 indexed citations

Chan, Tak Mao, Roberto Pecoits‐Filho, Anjay Rastogi, et al.. (2020). Roxadustat vs. Placebo or Epoetin Alfa Has No Clinically Meaningful Effect on Blood Pressure in Patients with Anemia of CKD. Journal of the American Society of Nephrology. 31(10S). 649–649. 2 indexed citations

O’Connell, Philip J., Mark Brown, Tak Mao Chan, et al.. (2020). The role of kidney transplantation as a component of integrated care for chronic kidney disease. Kidney International Supplements. 10(1). e78–e85. 12 indexed citations

Wong, Carlos King Ho, Julie Chen, Samuel Fung, et al.. (2018). Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis. Nephrology Dialysis Transplantation. 34(9). 1565–1576. 29 indexed citations

Yung, Susan & Tak Mao Chan. (2016). Anti-dsDNA antibodies and resident renal cells — Their putative roles in pathogenesis of renal lesions in lupus nephritis. Clinical Immunology. 185. 40–50. 58 indexed citations

10.

Wong, George Kwok Chu, Shui Lam, Ka Ming Ngai, et al.. (2013). Cognitive domain deficits in patients with aneurysmal subarachnoid haemorrhage at 1 year. Journal of Neurology Neurosurgery & Psychiatry. 84(9). 1054–1058. 40 indexed citations

11.

Shiu, Sammy W.M., et al.. (2013). Impact of serum amyloid A on cellular cholesterol efflux to serum in type 2 diabetes mellitus. Atherosclerosis. 231(2). 405–410. 38 indexed citations

12.

Rovin, Brad H., Samir V. Parikh, Lee A. Hebert, et al.. (2012). Lupus Nephritis. Clinical Journal of the American Society of Nephrology. 8(1). 147–153. 37 indexed citations

13.

Chan, Tak Mao, et al.. (2009). Phy06 Development of a Clinical Practice Guideline: “Home Oxygen Therapy for Adult Patients” Based On an Evidence-Based Approach. Hong Kong Journal of Occupational Therapy. 19(2). A4–A4. 1 indexed citations

14.

Chan, Tak Mao, Sydney Tang, Man Fai Lam, et al.. (2007). Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology. 12(6). 576–581. 57 indexed citations

15.

Lam, Man Fai, Joseph C.K. Leung, Wai Kei Lo, et al.. (2005). Mannose binding lectin level and polymorphism in patients on long-term peritoneal dialysis. Nephrology Dialysis Transplantation. 20(11). 2489–2496. 12 indexed citations

16.

Yip, Terence, et al.. (2005). Risk Factors and Outcomes of ESBL-producing E. coli Peritonitis in CAPD Patients. Hong Kong Journal of Nephrology. 7(2). A4–A4.

17.

Chan, Tak Mao. (2003). Different effects of amino acid-based dialysate from peritoneal dialysis patients on mesothelial cell utrastructure and function. 18. 1086–1094.

18.

Ngan, Roger K.C., Harry Yiu, W.H. Lau, et al.. (2002). Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Annals of Oncology. 13(8). 1252–1258. 137 indexed citations

19.

Lui, Sing Leung, et al.. (2001). NOSOCOMIAL OUTBREAK OF PARVOVIRUS B19 INFECTION IN A RENAL TRANSPLANT UNIT12. Transplantation. 71(1). 59–63. 36 indexed citations

20.

Lui, Sing‐Leung, Kwok‐Wah Chan, Fu–Keung Li, Ignatius K.P. Cheng, & Tak Mao Chan. (1998). Castleman’s Disease and Mesangial Proliferative Glomerulonephritis: The Role of Interleukin-6. The Nephron journals/Nephron journals. 78(3). 323–327. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact